Lupin is rolling out tolvaptan tablets, 15 mg, 30 mg, 45 mg, 60 mg and 90 mg in the United States. Lupin holds the exclusive first-to-file status for this product and will have 180-day generic ...

Lupin has received the Food and Drug Administration’s permission for tolvaptan tablets, 15 mg, 30 mg, 45 mg, 60 mg and 90 mg. Tolvaptan tablets are the generic of Otsuka’s Jynarque.

Lupin gains US FDA approval for Tolvaptan tablets in various dosages, marking a significant entry into the nephrology market. The tablets, bioequivalent to Otsuka's Jynarque, will be manufactured ...

Following the recent approval received from the United States Food and Drug Administration (FDA), global pharma major Lupin Limited (Lupin) announced the launch of tolvaptan tablets, 15 mg, 30 mg, 45 ...

"We are pleased to enclose a press release as regards, receipt of tentative U.S. FDA approval for the company’s abbreviated new drug application Tolvaptan tablets, 15 mg, 30 mg, 45 mg, 60 mg, and 90 ...

Global pharma major Lupin Limited (Lupin) announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application for tolvaptan ...

According to a press statement, this approval is granted to market the generic equivalent of Jynarque Tablets, 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg, of Otsuka Pharmaceutical Co., Ltd.

Lupin gains US FDA approval for Tolvaptan tablets in various dosages, marking a significant entry into the nephrology market. The tablets, bioequivalent to Otsuka's Jynarque, will be manufactured ...